Patents by Inventor Gregory Geba

Gregory Geba has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS AND COMPOSITIONS FOR REDUCING CENTRALIZED PAIN
    Publication number: 20250011408
    Abstract: Methods and compositions for treating centralized pain are disclosed. Methods and compositions for reducing pain or improving physical function are disclosed. In certain aspects, the subject has centralized pain and osteoarthritis of the knee and/or hip and the anti-NGF antibody is fasinumab.
    Type: Application
    Filed: November 18, 2022
    Publication date: January 9, 2025
    Inventors: Stephen DIMARTINO, Paula DAKIN, Gregory GEBA, Haitao GAO
  • METHODS FOR ATTENUATING ATOPIC MARCH BY ADMINISTERING AN IL-4/IL-13 ANTAGONIST
    Publication number: 20230220089
    Abstract: Methods are provided for preventing the development of a new allergic condition or the worsening of an existing concomitant allergic condition in a subject having an atopic disease such as atopic dermatitis. In one aspect, the methods comprise administering to the subject a course of therapy of an IL-4/IL-13 antagonist, such as an anti-IL-4R antibody or antigen-binding fragment thereof.
    Type: Application
    Filed: December 29, 2022
    Publication date: July 13, 2023
    Inventors: Gregory GEBA, Dateng LI, Judy Xiang LI
  • Pharmaceutical composition for safe and effective treatment of knee and/or hip pain
    Patent number: 11472870
    Abstract: A pharmaceutical composition and a method for treating knee and/or hip pain in a patient non-responsive or intolerant to standard analgesic therapy are disclosed. A pharmaceutical composition and a method for reducing risk for developing an arthropathy in a subject receiving an anti-NGF antibody for treatment of knee and/or hip pain are disclosed. Also provided herein are methods for monitoring safety of a treatment of knee and/or hip pain involving administration of an anti-NGF antibody. In certain aspects, the subject has osteoarthritis of the knee and/or hip and the anti-NGF antibody is fasinumab.
    Type: Grant
    Filed: August 9, 2019
    Date of Patent: October 18, 2022
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Gregory Geba, Paula Dakin, Stephen DiMartino, Haitao Gao, Sr., Jennifer Maloney, John Davis, Catherine Stehman Breen
  • Pharmaceutical Composition for Safe and Effective Treatment of Knee and/or Hip Pain
    Publication number: 20220041708
    Abstract: A pharmaceutical composition and a method for treating knee and/or hip pain in a patient non-responsive or intolerant to standard analgesic therapy are disclosed. A pharmaceutical composition and a method for reducing risk for developing an arthropathy in a subject receiving an anti-NGF antibody for treatment of knee and/or hip pain are disclosed. Also provided herein are methods for monitoring safety of a treatment of knee and/or hip pain involving administration of an anti-NGF antibody. In certain aspects, the subject has osteoarthritis of the knee and/or hip and the anti-NGF antibody is fasinumab.
    Type: Application
    Filed: October 26, 2021
    Publication date: February 10, 2022
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Gregory GEBA, Paula DAKIN, Stephen DIMARTINO, Haitao GAO, Jennifer MALONEY, John DAVIS, Catherine Stehman BREEN
  • PHARMACEUTICAL COMPOSITION FOR SAFE AND EFFECTIVE TREATMENT OF KNEE AND/OR HIP PAIN
    Publication number: 20200048337
    Abstract: A pharmaceutical composition and a method for treating knee and/or hip pain in a patient non-responsive or intolerant to standard analgesic therapy are disclosed. A pharmaceutical composition and a method for reducing risk for developing an arthropathy in a subject receiving an anti-NGF antibody for treatment of knee and/or hip pain are disclosed. Also provided herein are methods for monitoring safety of a treatment of knee and/or hip pain involving administration of an anti-NGF antibody. In certain aspects, the subject has osteoarthritis of the knee and/or hip and the anti-NGF antibody is fasinumab.
    Type: Application
    Filed: August 9, 2019
    Publication date: February 13, 2020
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Gregory Geba, Paula Dakin, Stephen DiMartino, Haltao Gao, Sr., Jennifer Maloney, John DAVIS, Catherine Stehman BREEN